By Christy Santhosh and Sriparna Roy Dec 11 (Reuters) - Eli Lilly said on Thursday its next-generation obesity drug helped ...

Dec 11 (Reuters) - Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of ...

By Christy Santhosh and Sriparna Roy Dec 11 (Reuters) - Eli Lilly said on Thursday its next-generation obesity drug helped ...

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

Eli Lilly will cut prices for its weight loss drug Zepbound, with single-dose vials now available for $299 per month through ...

Dec 1 (Reuters) - Eli Lilly said on Monday it has lowered the price of single-dose vials of its popular obesity drug Zepbound ...

This is the second time Eli Lilly has cut prices of Zepbound on LillyDirect. The pharmaceutical company said it is making the ...

Eli Lilly is cutting introductory Zepbound prices again, with the lowest dose now $299 monthly for cash-pay customers, a $50 ...

Some patients dropped out of the trial early because they had lost so much weight.

Regulators in Europe just backed Novo's heavyweight Wegovy--setting the stage for a head-to-head obesity drug showdown in ...

Eli Lilly & Co. is cutting the price for introductory doses of its weight-loss drug Zepbound again, as competition heats up ...